Abstract 1751P
Background
Standardized incidence and mortality rates are the default measures to describe cancer trends while survival assesses advances in cancer detection and treatment. Mortality compounds both incidence and survival but does not fully address age at death or long-term survival, both essential to quantify the cancer burden on society.
Methods
Using Swedish National Cancer and Cause of Death Register data together with publicly accessible projections of life expectancy, we calculated years of life lost (YLL) as the difference between age at cancer death and expected age at death for an individual of the corresponding age, sex, and birth year in the general population. All adults (18-95 years) with death reported as caused by one of the 10 solid tumors causing most deaths (lung, colorectal, prostate, pancreatic, breast, hepatobiliary, urinary, central nervous system, gastric cancer, or melanoma) in Sweden from 2010-2019, were included.
Results
When YLL were related and compared to mortality estimates in 2019 (Table), lung cancer (43,152 YLL) and colorectal cancer (32,340 YLL) remained at the top. Pancreatic cancer was up-ranked from 4th to 3rd place (22,592 YLL) and breast cancer from 5th to 4th place (21,810 YLL), while prostate cancer was down-ranked from 3rd to 5th place (17,380 YLL). In the table, a traditional approach ranking the 10 most common causes of cancer death in number of deaths and mortality rate (A), and new ranking using years of life lost approach (B), Sweden 2019.
Table: 1751P
A. Traditional approach | B. Years of life lost approach | ||||
Cancer site | Deaths | Mortality rate | Rank | Years of life lost | New rank |
Lung | 3144 | 38.7 | 1 | 43152 | 1 |
Colorectal | 2543 | 31.3 | 2 | 32340 | 2 |
Prostate | 2063 | 25.4 | 3 | 17380 | 5 |
Pancreatic | 1600 | 19.7 | 4 | 22592 | 3 |
Breast | 1335 | 16.5 | 5 | 21810 | 4 |
Hepatobiliary | 998 | 12.3 | 6 | 14568 | 6 |
Urinary | 740 | 9.1 | 7 | 7435 | 8 |
Central nervous system | 548 | 6.7 | 8 | 11628 | 7 |
Gastric | 510 | 5.8 | 9 | 7159 | 9 |
Melanoma skin | 472 | 6.3 | 10 | 6973 | 10 |
Assessing YLL trends over the period from 2010-2019, women consistently lost more life years due to lung and pancreatic cancer than men. A downward trend in colorectal cancer mortality was reflected as a YLL decline only among women but not men.
Conclusions
Although all vital statistics have inborn advantages and disadvantages, this study demonstrates that YLL is simple to calculate, intuitive to interpret, and is as a meaningful measure to be added to the statistical toolbox box when presenting and comparing cancer trends within and between populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Region Stockholm (grant number: FoUI-963792).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1746P - Unintended consequences: Working time directives and oncology staff implications
Presenter: Simon Barry
Session: Poster session 23
1747P - The need for a better discussion between doctors and patients with regards to fertility preservation and vaginal rehab after anti cervical cancer treatments
Presenter: Bar Levy
Session: Poster session 23
1748P - Tackling childhood obesity epidemic on southern Europe through soft drink advertisement policies: Should oncology societies have a say?
Presenter: Konstantinos Kamposioras
Session: Poster session 23
1749P - Prevention of modifiable cancer risks in informal family caregivers of cancer patients: Implementation and evaluation of a personalised primary prevention intervention (PREV-AIDANT)
Presenter: Beatrice Fervers
Session: Poster session 23
1752P - Clinical benefit of immunotherapies in advanced cancer in France: A population-based estimate from 2014 to 2021
Presenter: Isabelle Borget
Session: Poster session 23
1753P - Universal DPYD genotyping in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy
Presenter: Claudia Cardone
Session: Poster session 23
1754P - Towards a next-generation sequencing/comprehensive genomic profiling value framework: Systematic review for identifying new domains and adapting a diagnostic test value framework in Europe
Presenter: Federico Augustovski
Session: Poster session 23
1755P - Carbohydrate quality index and incidence of obesity-related cancers: The Seguimiento Universidad de Navarra (SUN) project
Presenter: Maria Olmedo López-frías
Session: Poster session 23
1756P - Vizcan: A Swedish population-based study to address cancer outcomes using an interactive platform
Presenter: Anders Berglund
Session: Poster session 23